financetom
Business
financetom
/
Business
/
Johnson & Johnson New Trial Request Denied in Mesothelioma Lawsuit
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Johnson & Johnson New Trial Request Denied in Mesothelioma Lawsuit
Oct 5, 2024 2:07 AM

01:59 PM EDT, 10/04/2024 (MT Newswires) -- Johnson & Johnson's ( JNJ ) request for a new trial on an already decided mesothelioma lawsuit was denied by a circuit court in Cook County, Illinois.

The court upheld the jury verdict that awarded $45 million in the asbestos-related death of Theresa Garcia, the law firm representing her family said Friday.

Johnson & Johnson ( JNJ ) did not immediately respond to MT Newswires' request for comment.

Price: 159.70, Change: -0.81, Percent Change: -0.50

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Paycom Software Insider Sold Shares Worth $617,257, According to a Recent SEC Filing
Paycom Software Insider Sold Shares Worth $617,257, According to a Recent SEC Filing
Aug 12, 2024
04:48 PM EDT, 08/12/2024 (MT Newswires) -- Chad R. Richison, 10% Owner, Director, CEO, President and Chairman, on August 09, 2024, sold 3,900 shares in Paycom Software ( PAYC ) for $617,257. Following the Form 4 filing with the SEC, Richison has control over a total of 6,557,841 shares of the company, with 2,980,808 shares held directly and 3,577,033 controlled...
Immunome Q2 Net Loss Widens, Revenue Drops
Immunome Q2 Net Loss Widens, Revenue Drops
Aug 12, 2024
04:45 PM EDT, 08/12/2024 (MT Newswires) -- Immunome ( IMNM ) reported Q2 net loss late Monday of $0.60 per diluted share, widening from $0.46 a year earlier. Analysts polled by Capital IQ expected a loss of $0.39. Revenue for the quarter ended June 30 was $2.4 million, down from $4.3 million a year earlier. Analysts polled by Capital IQ...
Net Power Q2 Net Loss Narrows, Revenue Rises
Net Power Q2 Net Loss Narrows, Revenue Rises
Aug 12, 2024
04:53 PM EDT, 08/12/2024 (MT Newswires) -- Net Power ( NPWR ) reported a Q2 net loss late Monday of $0.06 per diluted share, narrowing from a loss of $4.51 a year earlier. Analysts polled by Capital IQ expected a loss of $0.05 normalized. Revenue for the quarter ended June 30 was $238,000, up from $125,000 a year earlier. Comparable...
Astria Therapeutics Q2 Loss Narrows Less Than Expected
Astria Therapeutics Q2 Loss Narrows Less Than Expected
Aug 12, 2024
04:52 PM EDT, 08/12/2024 (MT Newswires) -- Astria Therapeutics ( ATXS ) reported a Q2 loss late Monday of $0.43 per diluted share, compared with a loss of $0.45 a year earlier. Four analysts polled by Capital IQ expected a loss of $0.40 per share. As expected, no revenue for the quarter ended June 30 was reported. As of June...
Copyright 2023-2026 - www.financetom.com All Rights Reserved